What is the value and structure of Samsung Biologics' bid for PolyPeptide, and what premium does it offer over PolyPeptide's last closing share price?

Samsung Biologics will launch a 1.46 billion Swiss francs ($1.81 billion) all-cash tender offer for PolyPeptide at 44.31 Swiss francs per share, representing a premium of about 6.1% to PolyPeptide's last closing price of 41.75 Swiss francs on Friday.

What strategic rationale did Samsung Biologics provide for acquiring PolyPeptide, and what is the expected timeline for the bid?

The takeover would expand Samsung Biologics' capabilities in peptide-based therapeutics, including fast-growing obesity and diabetes treatments such as GLP-1 drugs; the tender offer is expected to launch by the end of August and close by year-end.

Samsung Biologics to launch $1.8 billion all-cash bid for PolyPeptide

Jul 19, 2026

Samsung Biologics plans a $1.8 billion cash acquisition of Swiss drugmaker PolyPeptide to expand capabilities in peptide-based therapeutics like GLP-1 drugs. The offer includes a 6.1% premium and aims to make PolyPeptide a wholly owned unit by year-end.

reuters

2026-04-03

Samsung Biologics completes $280M acquisition of GSK manufacturing facility in Maryland

2026-07-19

Samsung Biologics to launch $1.8 billion all-cash bid for PolyPeptide

Samsung Biologics to launch $1.8 billion all-cash bid for PolyPeptide

FAQ